On June 10, 2021 Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, reported that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18 (Press release, Notable Labs, JUN 10, 2021, View Source [SID1234583857]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, Notable will be seeking partnering opportunities to partner on and in-license investigational treatments for hematological cancers. Notable’s focus is to achieve and accelerate their development by targeting patient populations who will respond based on its prediction technology platform.

Dr. Thomas Bock, CEO of Notable said, "This conference comes at a pivotal time to expand our collaboration with current and prospective partners and leverage the recent progress we achieved for our prediction platform capabilities." Matt De Silva, Founder and Executive Chairman of the board added, "In the past months we have advanced and grown extremely fast, propelling our insights across drug classes and diseases. We are thrilled to share that excitement with potential new collaborators."

The BIO Digital conference provides access to almost 3,000 U.S. and international life science companies. The virtual gathering of the global biotech industry provides access to key partners via BIO’s One-on-One Partnering, critical education including policy, industry trends, breakthrough therapies, and patient access.